OPPM
Opus Point Partners Management Portfolio holdings
AUM
$46.9M
This Quarter Return
-1.31%
1 Year Return
-4.17%
3 Year Return
+83.22%
5 Year Return
+175.29%
10 Year Return
–
AUM
$58.3M
AUM Growth
+$58.3M
(-9.3%)
Cap. Flow
-$3.29M
Cap. Flow
% of AUM
-5.64%
Top 10 Holdings %
Top 10 Hldgs %
53.36%
Holding
75
New
1
Increased
16
Reduced
1
Closed
13
Top Buys
| 1 |
Sarepta Therapeutics
SRPT
|
$319K |
| 2 |
Exact Sciences
EXAS
|
$288K |
| 3 |
Biogen
BIIB
|
$263K |
| 4 |
Nektar Therapeutics
NKTR
|
$78.2K |
| 5 |
Ligand Pharmaceuticals
LGND
|
$41.8K |
Top Sells
| 1 |
Regenxbio
RGNX
|
$506K |
| 2 |
CLLS
Cellectis
CLLS
|
$409K |
| 3 |
Supernus Pharmaceuticals
SUPN
|
$408K |
| 4 |
RUBY
Rubius Therapeutics, Inc
RUBY
|
$391K |
| 5 |
Wave Life Sciences
WVE
|
$377K |
Sector Composition
| 1 | Healthcare | 64.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
IQVIA
IQV
$32.4B
| $319K | 0.47% |
1,985
| – | – |
|
52
Charles River Laboratories
CRL
$8.04B
| $300K | 0.44% |
2,112
| – | – |
|
53
Grifois
GRFS
$6.78B
| $278K | 0.41% |
13,196
+114
| +0.9% | +$2.4K |
|
54
Gilead Sciences
GILD
$140B
| $276K | 0.41% |
4,082
+415
| +11% | +$28.1K |
|
|
55
Biogen
BIIB
$19.4B
| $263K | 0.39% |
+1,123
| New | +$263K |
|
56
Amgen
AMGN
$155B
| $257K | 0.38% |
1,397
+155
| +12% | +$28.5K |
|
57
Neurocrine Biosciences
NBIX
$13.8B
| $254K | 0.38% |
3,012
+205
| +7% | +$17.3K |
|
58
Exelixis
EXEL
$10.1B
| $244K | 0.36% |
11,440
| – | – |
|
|
59
Ligand Pharmaceuticals
LGND
$3.15B
| $241K | 0.36% |
2,111
+366
| +21% | +$41.8K |
|
60
Agios Pharmaceuticals
AGIO
$2.19B
| $240K | 0.36% |
4,806
| – | – |
|
61
FibroGen
FGEN
$47.8M
| $221K | 0.33% |
4,883
+56
| +1% | +$2.54K |
|
|
SCTL
62
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
| $115K | 0.17% |
11,353
| – | – |
|
63
AC Immune
ACIU
$205M
| – | – |
-39,801
| Closed | -$201K |
|
64
Alkermes
ALKS
$4.78B
| – | – |
-7,722
| Closed | -$282K |
|
|
CLLS
65
Cellectis
CLLS
$258M
| – | – |
-22,309
| Closed | -$409K |
|
66
CytomX Therapeutics
CTMX
$336M
| – | – |
-25,284
| Closed | -$272K |
|
67
Precigen
PGEN
$1.34B
| – | – |
-32,284
| Closed | -$170K |
|
|
68
Regenxbio
RGNX
$451M
| – | – |
-8,832
| Closed | -$506K |
|
69
Sangamo Therapeutics
SGMO
$157M
| – | – |
-33,529
| Closed | -$320K |
|
|
70
Supernus Pharmaceuticals
SUPN
$2.53B
| – | – |
-11,648
| Closed | -$408K |
|
71
United Therapeutics
UTHR
$13.8B
| – | – |
-2,199
| Closed | -$258K |
|
|
72
Wave Life Sciences
WVE
$1.53B
| – | – |
-9,716
| Closed | -$377K |
|
73
Xencor
XNCR
$580M
| – | – |
-10,935
| Closed | -$340K |
|
|
SURF
74
DELISTED
Surface Oncology, Inc. Common Stock
SURF
| – | – |
-53,063
| Closed | -$253K |
|
|
RUBY
75
DELISTED
Rubius Therapeutics, Inc
RUBY
| – | – |
-21,610
| Closed | -$391K |
|